130 related articles for article (PubMed ID: 38030195)
21. A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302).
Tamura S; Taniguchi H; Nishikawa K; Imamura H; Fujita J; Takeno A; Matsuyama J; Kimura Y; Kawada J; Hirao M; Hirota M; Fujitani K; Kurokawa Y; Sakai D; Kawakami H; Shimokawa T; Satoh T
Int J Clin Oncol; 2020 Dec; 25(12):2035-2043. PubMed ID: 32926227
[TBL] [Abstract][Full Text] [Related]
22. Clinical usefulness of ramucirumab plus paclitaxel for unresectable and recurrent gastric cancer.
Hayase S; Yamada L; Ujiie D; Nirei A; Tada T; Hanayama H; Monma T; Saze Z; Ohki S; Kono K
Fukushima J Med Sci; 2019; 65(1):6-12. PubMed ID: 30996218
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the safety of ramucirumab in Japanese patients with advanced gastric cancer.
Iwai M; Ito D; Asano H; Adachi S; Okada K; Kimura M; Usami E; Matsuo K; Yoshimura T; Teramachi H
Pharmazie; 2018 May; 73(5):309-312. PubMed ID: 29724300
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG).
Jung M; Ryu MH; Oh DY; Kang M; Zang DY; Hwang IG; Lee KW; Kim KH; Shim BY; Song EK; Sym SJ; Han HS; Park YL; Kim JS; Lee HW; Lee MH; Koo DH; Song HS; Lee N; Yang SH; Choi DR; Hong YS; Lee KE; Maeng CH; Baek JH; Kim S; Kim YH; Rha SY; Cho JY; Kang YK
Gastric Cancer; 2018 Sep; 21(5):819-830. PubMed ID: 29427038
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer.
Sasaki Y; Nishina T; Yasui H; Goto M; Muro K; Tsuji A; Koizumi W; Toh Y; Hara T; Miyata Y
Cancer Sci; 2014 Jul; 105(7):812-7. PubMed ID: 24716542
[TBL] [Abstract][Full Text] [Related]
26. Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer.
Nakajima TE; Kadowaki S; Minashi K; Nishina T; Yamanaka T; Hayashi Y; Izawa N; Muro K; Hironaka S; Kajiwara T; Kawakami Y
Clin Cancer Res; 2021 Feb; 27(4):1029-1036. PubMed ID: 33262133
[TBL] [Abstract][Full Text] [Related]
27. A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites.
Matsumoto H; Kawazoe A; Shimada K; Fukuoka S; Kuboki Y; Bando H; Kojima T; Ohtsu A; Yoshino T; Doi T; Shitara K
BMC Cancer; 2018 Jan; 18(1):120. PubMed ID: 29385993
[TBL] [Abstract][Full Text] [Related]
28. A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
Jiang H; Qian J; Zhao P; Zhang X; Zheng Y; Mao C; Zheng Y; Chen L; Wang Y; Mou H; Fang W; Teng L; Xu N
Cancer Chemother Pharmacol; 2015 Jul; 76(1):197-203. PubMed ID: 26013324
[TBL] [Abstract][Full Text] [Related]
29. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
Fuchs CS; Shitara K; Di Bartolomeo M; Lonardi S; Al-Batran SE; Van Cutsem E; Ilson DH; Alsina M; Chau I; Lacy J; Ducreux M; Mendez GA; Alavez AM; Takahari D; Mansoor W; Enzinger PC; Gorbounova V; Wainberg ZA; Hegewisch-Becker S; Ferry D; Lin J; Carlesi R; Das M; Shah MA;
Lancet Oncol; 2019 Mar; 20(3):420-435. PubMed ID: 30718072
[TBL] [Abstract][Full Text] [Related]
30. Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma.
Rogers JE; Xiao L; Amlashi FG; Elimova E; Blum Murphy MA; Sanders E; Shanbhag N; Thomas I; Ajani JA
Oncology; 2019; 96(5):252-258. PubMed ID: 30893708
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy and Safety of Paclitaxel plus Ramucirumab Therapy for Unresectable or Recurrent Gastric Cancer].
Tsujio G; Toyokawa T; Fukuoka T; Tamura T; Ohira G; Shibutani M; Yamazoe S; Nagahara H; Kimura K; Amano R; Tanaka H; Muguruma K; Yashiro M; Maeda K; Hirakawa K; Ohira M
Gan To Kagaku Ryoho; 2019 May; 46(5):895-899. PubMed ID: 31189811
[TBL] [Abstract][Full Text] [Related]
32. Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16).
Han HS; Kim BJ; Jee HJ; Ryu MH; Park SH; Rha SY; Kim JG; Bae WK; Lee KW; Oh DY; Kim IH; Sym SJ; Oh SY; Kim HS; Byun JH; Kim DS; Suh YJ; An H; Zang DY
Ther Adv Med Oncol; 2021; 13():17588359211042812. PubMed ID: 34552667
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer.
Kato K; Chin K; Yoshikawa T; Yamaguchi K; Tsuji Y; Esaki T; Sakai K; Kimura M; Hamaguchi T; Shimada Y; Matsumura Y; Ikeda R
Invest New Drugs; 2012 Aug; 30(4):1621-7. PubMed ID: 21728023
[TBL] [Abstract][Full Text] [Related]
34. A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer.
Lee JJ; Kim SY; Chung HC; Lee KH; Song HS; Kang WK; Hong YS; Choi IS; Lee YY; Woo IS; Choi JH
Cancer Chemother Pharmacol; 2009 May; 63(6):1083-90. PubMed ID: 18813927
[TBL] [Abstract][Full Text] [Related]
35. Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603.
Kawamoto Y; Yuki S; Sawada K; Nakamura M; Muto O; Sogabe S; Shindo Y; Ishiguro A; Sato A; Tsuji Y; Dazai M; Okuda H; Meguro T; Harada K; Sekiguchi M; Okada K; Ito YM; Sakata Y; Sakamoto N; Komatsu Y
Oncologist; 2022 Aug; 27(8):e642-e649. PubMed ID: 35579511
[TBL] [Abstract][Full Text] [Related]
36. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
37. Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).
Takiuchi H; Goto M; Imamura H; Furukawa H; Imano M; Imamoto H; Kimura Y; Ishida H; Fujitani K; Narahara H; Shimokawa T
Jpn J Clin Oncol; 2008 Mar; 38(3):176-81. PubMed ID: 18281707
[TBL] [Abstract][Full Text] [Related]
38. Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy.
Roviello G; Martina C; Winchler C; De Gennaro Aquino I; Papa F; Buttitta E; Rossi G; Antonuzzo L
J Gastrointest Cancer; 2023 Sep; 54(3):802-808. PubMed ID: 36109437
[TBL] [Abstract][Full Text] [Related]
39. Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study.
Zheng Y; Fang W; Mao C; Qian J; Zhao P; Zhang X; Jiang H; Zheng Y; Xu N
Cancer Chemother Pharmacol; 2014 Sep; 74(3):503-9. PubMed ID: 25038612
[TBL] [Abstract][Full Text] [Related]
40. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]